Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Share-based Compensation: 2013-2025

Historic Share-based Compensation for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $12.3 million.

  • KalVista Pharmaceuticals' Share-based Compensation fell 71.42% to $3.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was $22.4 million, marking a year-over-year increase of 2.32%. This contributed to the annual value of $12.3 million for FY2025, which is 43.92% down from last year.
  • According to the latest figures from FY2025, KalVista Pharmaceuticals' Share-based Compensation is $12.3 million, which was down 43.92% from $21.9 million recorded in FY2024.
  • KalVista Pharmaceuticals' Share-based Compensation's 5-year high stood at $21.9 million during FY2024, with a 5-year trough of $7.1 million in FY2021.
  • Moreover, its 3-year median value for Share-based Compensation was $12.3 million (2025), whereas its average is $14.7 million.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Share-based Compensation soared by 120.87% in 2024 and then crashed by 43.92% in 2025.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Share-based Compensation stood at $7.1 million in 2021, then spiked by 55.75% to $11.1 million in 2022, then fell by 10.50% to $9.9 million in 2023, then surged by 120.87% to $21.9 million in 2024, then crashed by 43.92% to $12.3 million in 2025.